Market Cap | 233.43M | P/E | - | EPS this Y | -16.20% | Ern Qtrly Grth | - |
Income | -52.34M | Forward P/E | -5.43 | EPS next Y | 52.30% | 50D Avg Chg | -6.00% |
Sales | 391.69k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 26.00% |
Dividend | N/A | Price/Book | 1.93 | EPS next 5Y | - | 52W High Chg | -17.00% |
Recommedations | 1.60 | Quick Ratio | 9.22 | Shares Outstanding | 70.81M | 52W Low Chg | 136.00% |
Insider Own | 15.97% | ROA | -24.76% | Shares Float | 37.59M | Beta | 0.69 |
Inst Own | 64.68% | ROE | -47.57% | Shares Shorted/Prior | 2.80M/3.67M | Price | 3.31 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 300,562 | Target Price | 7.75 |
Oper. Margin | -13,978.47% | Earnings Date | May 3 | Volume | 423,490 | Change | -7.15% |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
B. Riley Securities | Buy | Apr 30, 24 |
HC Wainwright & Co. | Buy | Apr 29, 24 |
Wedbush | Outperform | Apr 5, 24 |
BTIG | Buy | Dec 21, 23 |
JonesTrading | Buy | Jun 14, 23 |
Ladenburg Thalmann | Buy | May 2, 23 |
Citigroup | Neutral | Aug 29, 22 |
Citigroup | Neutral | May 20, 22 |
Citigroup | Neutral | Aug 25, 21 |